BioVie, Inc. (BIVI)
1.43
+0.05
(+3.62%)
USD |
NASDAQ |
Oct 30, 16:00
1.42
-0.01
(-0.70%)
Pre-Market: 20:00
BioVie EPS Diluted (Quarterly) : -0.7485 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.7485 |
| March 31, 2026 | -0.6986 |
| December 31, 2025 | -0.7663 |
| September 30, 2025 | -0.984 |
| June 30, 2025 | -1.823 |
| March 31, 2025 | -0.1507 |
| December 31, 2024 | -4.554 |
| September 30, 2024 | -0.6997 |
| June 30, 2024 | -0.7982 |
| March 31, 2024 | -1.999 |
| December 31, 2023 | -2.201 |
| September 30, 2023 | -2.915 |
| June 30, 2023 | -2.501 |
| March 31, 2023 | -4.258 |
| December 31, 2022 | -5.033 |
| September 30, 2022 | -3.828 |
| June 30, 2022 | -3.238 |
| March 31, 2022 | -2.818 |
| December 31, 2021 | -2.169 |
| September 30, 2021 | -2.336 |
| June 30, 2021 | -58.90 |
| March 31, 2021 | -2.150 |
| December 31, 2020 | -2.197 |
| September 30, 2020 | -77.47 |
| June 30, 2020 | -36.80 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.7068 |
| December 31, 2019 | 12.86 |
| September 30, 2019 | -50.62 |
| June 30, 2019 | -2.488 |
| March 31, 2019 | -3.35 |
| December 31, 2018 | -1.988 |
| September 30, 2018 | -1.975 |
| June 30, 2018 | -7.312 |
| March 31, 2018 | -12.50 |
| December 31, 2017 | -12.50 |
| September 30, 2017 | -12.50 |
| June 30, 2017 | -6.025 |
| March 31, 2017 | -2.438 |
| December 31, 2016 | -5.112 |
| September 30, 2016 | -5.038 |
| June 30, 2016 | -3.862 |
| March 31, 2016 | -0.825 |
| December 31, 2015 | -0.7125 |
| September 30, 2015 | -0.7875 |
| June 30, 2015 | -0.7875 |
| March 31, 2015 | -0.70 |
| December 31, 2014 | -1.012 |
| September 30, 2014 | -0.8375 |
| June 30, 2014 | -2.488 |
| March 31, 2014 | -0.6875 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Agenus, Inc. | -0.0146 |
| Amgen, Inc. | 4.366 |
| Anika Therapeutics, Inc. | 0.2412 |
| BioCryst Pharmaceuticals, Inc. | 0.2957 |
| Imunon, Inc. | -0.5412 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -5.646M |
| Total Expenses (Quarterly) | 5.646M |
| Enterprise Value | 2.084M |
| Earnings Yield | -223.6% |
| Normalized Earnings Yield | -223.59 |